Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

The cell and gene therapy (CAGT) pipeline represents incredible promise for the patients who need these products, many of whom have rare conditions without approved treatments or others who have exhausted treatment options. In bringing these novel therapies to market, sponsors face new regulatory and manufacturing challenges, operational complexity, and obstacles to market access.

Parexel helps sponsors innovate in this growing but uncertain space, so our experienced colleagues have strategized approaches to the persistent and prevalent barriers that CAGT developers may encounter. In this guide, we share some of those strategies — actionable insights for protecting the potential of your product in every phase of development.

Open PDF

Return to Insights Center

Related Insights


New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023


CAR-T boxed warnings: What comes next?

Mar 6, 2024


Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024


Cell & Gene Therapies: A Regulatory Update

Jul 22, 2022


CAR-T boxed warnings: regulatory precedents and opportunities

Feb 9, 2024


CAR-T product development: an assessment of FDA’s final guidance for industry

Feb 27, 2024


Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021


Rare endpoints: Delivering on unmet patient needs

May 7, 2024


Three ways to improve your chances that insurers will pay for a new CGT

Feb 18, 2021


Regulatory, clinical and logistics challenges of ATMPs in clinical research

Apr 22, 2021


SITC Crisis in Clinical Research Virtual Summit – Collaborating to Drive Change

Aug 24, 2022


RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

Jun 16, 2022